Proviva Therapeutics, a Shanghai-based clinical-stage biotechnology company, has reportedly secured USD 18 million in a Series A financing round led by Lapam Capital, Ennovation Ventures, and Sangel Capital. The funds raised will be directed towards the clinical advancement of the company’s core product, PTX-912.
Specializing in the development of next-generation cytokine anti-tumor immunotherapies, Proviva Therapeutics’ pipeline includes PTX-912, a next-generation immune cell targeted interleukin-2 (IL-2) prodrug fusion protein. This product is developed through the company’s Crossover cytokine prodrug technology platform, which aims to enhance the efficacy and safety of cytokine-based therapies.- Flcube.com
